Literature DB >> 16254306

Commissioning for rare diseases: view from the frontline.

Amanda Burls1, Daphne Austin, David Moore.   

Abstract

Mesh：

Year:  2005        PMID： 16254306      PMCID： PMC1273463          DOI： 10.1136/bmj.331.7523.1019

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

Review 1.  Orphan drugs and the NHS: should we value rarity?

Authors:  Christopher McCabe; Karl Claxton; Aki Tsuchiya
Journal:  BMJ       Date:  2005-10-29

Review 2.  A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.

Authors:  M Connock; A Juarez-Garcia; E Frew; A Mans; J Dretzke; A Fry-Smith; D Moore
Journal:  Health Technol Assess       Date:  2006-06       Impact factor: 4.014
  2 in total
  12 in total

1.  Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.

Authors:  James W Dear; Pajaree Lilitkarntakul; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

Review 2.  Economic evaluations in the canadian common drug review.

Authors:  Andreas Laupacis
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Orphan drugs for rare diseases: is it time to revisit their special market access status?

Authors:  Steven Simoens; David Cassiman; Marc Dooms; Eline Picavet
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

Review 4.  Unintended effects of orphan product designation for rare neurological diseases.

Authors:  Sinéad M Murphy; Araya Puwanant; Robert C Griggs
Journal:  Ann Neurol       Date:  2012-10       Impact factor: 10.422

Review 5.  A systematic review of moral reasons on orphan drug reimbursement.

Authors:  Bettina M Zimmermann; Johanna Eichinger; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2021-06-30       Impact factor: 4.123

6.  The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK.

Authors:  David Moore; Martin J Connock; Ed Wraith; Christine Lavery
Journal:  Orphanet J Rare Dis       Date:  2008-09-16       Impact factor: 4.123

7.  Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.

Authors:  Laura Gutierrez; Julien Patris; Adam Hutchings; Warren Cowell
Journal:  Orphanet J Rare Dis       Date:  2015-05-03       Impact factor: 4.123

8.  Oncologist Perspectives on Rare Cancer Care: A Nationwide Survey.

Authors:  Dong Wook Shin; Juhee Cho; Hyung Kook Yang; So Young Kim; Su Hyun Lee; Beomseok Suh; Hee-Young Shin; Hyun Joo Lee; Dae Ghon Kim; Jong Hyock Park
Journal:  Cancer Res Treat       Date:  2015-01-05       Impact factor: 4.679

9.  Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain.

Authors:  Carlos Crespo; Estela Moreno; Jordi Sierra; Suzan Serip; Marta Rubio
Journal:  Health Econ Rev       Date:  2013-12-05

10.  Orphan drugs expenditure in the Netherlands in the period 2006-2012.

Authors:  Tim A Kanters; Adri Steenhoek; Leona Hakkaart
Journal:  Orphanet J Rare Dis       Date:  2014-10-11       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.